Company intelligence / Profile preview

BaroSense

Redwood City, California, United Statesleti-cea.com ↗

Ownership: Private
Employees: ~4
Development stage: Other

Overview

BaroSense developed minimally invasive, reversible endoscopic devices as alternatives to traditional bariatric surgery for the treatment of obesity. Their approach aimed to reduce complications and improve safety compared to incision-based procedures. The company's assets were sold in 2013 and it does not appear to be currently active or developing new products.

Therapeutic areas: Endocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on BaroSense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BaroSense.

Explore the full profile